Minerva Neurosciences, Inc. (NERV) surged 339.33% to trade at $11.73, up $9.06, after announcing a $200 million financing deal with institutional investors to advance its schizophrenia drug candidate, roluperidone.
The agreement provides $80 million upfront, another $80 million through Tranche A warrants, and $40 million via milestone-based Tranche B warrants. The funding will help support a confirmatory Phase 3 trial, NDA resubmission, and potential U.S. commercial launch.
On Tuesday, NERV opened at $3.02, reached a high of $12.15, and a low of $2.97, compared to a previous close of $2.67 on the Nasdaq Capital Market. Trading volume topped 70 million shares, significantly above its average of 0.8 million. The stock's 52-week range is $1.03 - $12.15.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.